FDA ADVISORY PANEL MEETING SCHEDULED FOR ALBUNEX
FDA ADVISORY PANEL MEETING SCHEDULED FOR ALBUNEX SAN DIEGO, June 16 /PRNewswire/ -- Molecular Biosystems Inc.
(NYSE: MB) (MBI) today announced that its cardiac ultrasound contrast imaging agent, Albunex(R), will be reviewed by the Food and Drug Administration's Radiology Device Advisory Panel on July 14, 1992.
The advisory panel will review the use of Albunex for use with 2-D echocardiography (ultrasound of the heart). Albunex for this application is the first in a product line of planned ultrasound contrast imaging agents. Subsequent applications may include additional cardiovascular indications, including myocardial perfusion, as well as the enhancement of liver and kidney ultrasound imaging. Molecular Biosystems Inc., based in San Diego, is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound, magnetic resonance imaging, and computed tomography. Its flagship product, Albunex, is currently in the final stages of the FDA's pre-market approval process. MBI's marketing and distribution partners for Albunex include Mallinckrodt Medical Inc., IMCERA Group (NYSE: IMA), Shionogi & Co. Ltd. and Hafslund Nycomed AS. -0- 6/16/92 /CONTACT: Beth Field Wallace of Molecular Biosystems, 619-452-0681/ (MB IMA) CO: Molecular Biosystems Inc. ST: California IN: MTC SU: EH-KJ -- SD001 -- 0507 06/16/92 09:03 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 16, 1992|
|Previous Article:||INDE TO ACQUIRE KEAP COMMUNICATIONS|
|Next Article:||CIMCO REPORTS RESULTS FOR FOURTH QUARTER AND FISCAL YEAR|